Stocks
OHR PHARMACEUTICAL INCOHRP
HealthcareBiotechnology
A clinical-stage biopharmaceutical company developing oral small-molecule drugs for central nervous system disorders, including treatments for epilepsy and neuropathic pain. Its lead candidate, OHR/AV-101, targets the NMDA receptor pathway and has advanced through Phase 2 trials. Investors track the company for its potential in addressing unmet needs in CNS therapeutics.
Congressional Interest in OHR PHARMACEUTICAL INC (OHRP)
1 member of Congress has disclosed 1 trade in OHR PHARMACEUTICAL INC (OHRP), a Healthcare company. The buy/sell breakdown shows 0 purchases versus 1 sale, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
1
Unique Politicians
1
Buys
0
Sells
1
Who in Congress Is Trading OHRP?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2015-03-24 | MICHAEL T. MCCAUL | sell | $1K-$15K |